Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer; HER2-positive; Metastatic
Conditions
Breast Cancer; HER2-positive; Metastatic
Trial Timeline
Apr 26, 2021 → Dec 30, 2029
NCT ID
NCT04784715About Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab is a phase 3 stage product being developed by Daiichi Sankyo for Breast Cancer; HER2-positive; Metastatic. The current trial status is active. This product is registered under clinical trial identifier NCT04784715. Target conditions include Breast Cancer; HER2-positive; Metastatic.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer; HER2-positive; Metastatic were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04784715 | Phase 3 | Active |
Competing Products
20 competing products in Breast Cancer; HER2-positive; Metastatic